SCHEMBL25219590

SCHEMBL25219590

CN1CCC(C(=O)Nc2ncc(-c3cc[n+]([O-])cc3)s2)CC1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 1/20 0.76
▸ GSK3B P49841 9/20 0.56
▸ DYRK1A Q13627 9/20 0.56
▸ WNT1 P04628 5/20 0.56
▸ UCHL1 P09936 2/20 0.52
▸ USP30 Q70CQ3 2/20 0.48
▸ CCNE2 O96020 1/20 0.45
▸ CCNE1 P24864 1/20 0.45
▸ CDK2 P24941 1/20 0.45
▸ CNR2 P34972 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HDAC3 O15379 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ KIT P10721 1/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ KCNQ1 P51787 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25606129 0.90 MKNK1 (0.77) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL25610302 0.87 MKNK1 (0.72) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL25609256 0.83 MKNK1 (0.81) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL25605170 0.81 MKNK1 (0.74) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL25611765 0.78 DYRK1A (0.74) MKNK1GSK3BDYRK1AWNT1
SCHEMBL25602720 0.77 DYRK1A (0.77) MKNK1GSK3BDYRK1AWNT1
SCHEMBL31501400 0.77 DYRK1A (0.77) MKNK1GSK3BDYRK1AWNT1
SCHEMBL25602732 0.77 MKNK1 (0.69) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL31272043 0.76 MKNK1 (0.66) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL30481303 0.76 GSK3B (0.70) MKNK1GSK3BDYRK1AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS PROTHENA BIOSCIENCES INC 2025-02-27 — — US disclosed
EP-4444421-A2 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS Prothena Biosciences Limited (IE) 2024-10-16 — — EP disclosed
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 — — WO disclosed
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS DYRK1A, DYRK2, DYRK1B MKNK1 105/4885GSK3B 121/4885DYRK1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback